Article Text

Download PDFPDF

Original research
Endovascular therapy yields significantly superior outcomes for large vessel occlusions compared with intravenous thrombolysis: is it time to randomize?
  1. Ansaar T Rai1,
  2. Jeffrey S Carpenter1,
  3. Karthikram Raghuram2,
  4. Thomas D Roberts1,
  5. Daniel Rodgers1,
  6. Gerald R Hobbs3
  1. 1Interventional Neuroradiology, West Virginia University Hospital, Morgantown, West Virginia, USA
  2. 2Department of Radiology, St Luke's Medical Center, Milwaukee, Wisconsin, USA
  3. 3Department of Biostatistics, West Virginia University, Morgantown, West Virginia, USA
  1. Correspondence to Dr A T Rai, Interventional Neuroradiology, West Virginia University Hospital, One Medical Center Drive, Morgantown, WV 26508, USA; ansaar.rai{at}


Background and purpose We compared outcomes between endovascular (EV) therapy and intravenous (IV) thrombolysis in large vessel strokes.

Methods 223 patients who had received either IV (n=100) or EV (n=123) therapy were analyzed. Only patients with strokes involving the internal carotid artery terminus (ICA-T, n=45), the middle cerebral artery (M1, n=107) or the bifurcation branches (M2, n=71) were included. The primary endpoint was 3 month outcome based on the modified Rankin Scale (mRS) score, good-outcome defined as mRS ≤2.

Results The good outcome was 44.7% in the EV group and 26% in the IV group (p=0.003, OR 2.3, 95% CI 1.3 to 4.1). There was no difference in mortality or hemorrhage. For ICA-T occlusions, the good outcome was 27.6% in the EV and 0% in the IV group (p=0.004); for M1 occlusions, 40.6% in the EV versus 10.5% in the IV group (p=0.0006, OR 5.8, 95% CI 1.9 to 18.2); and for M2 occlusions, 76% in the EV versus 47.8% in the IV group (p=0.01, OR 3.5, 95% CI 1.2 to 10.2). For M1 occlusions, the death rate was 27.5% for the EV compared with 57.9% for the IV group (p=0.002, OR 3.6, 95% CI 1.6 to 8.3) with no difference observed in mortality for ICA-T or M2 occlusions. In the univariate analysis, age, National Institutes of Health Stroke Scale score and occlusion site were significant predictors of outcome and mortality (p<0.0001 for all). In the multivariable analysis, EV therapy (p=0.0004, OR 3.9, 95% CI 1.8 to 9) and younger age (p<0.0001, OR 0.96, 95% CI 0.9 to 0.98) were significant independent predictors of good outcome.

Conclusions There are significantly higher odds of a favorable outcome with EV compared with IV therapy for large vessel strokes. The data support the rationale of a randomized trial for large vessel occlusions.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Intravenous (IV) thrombolysis is the primary treatment for all patients with acute ischemic stroke (AIS) and improves outcomes compared with placebo.1 Endovascular (EV) therapies have shown effectiveness in revascularization of acutely occluded cerebral blood vessels, especially the proximal larger vessels.2–6

Large vessel occlusions (LVOs) are responsible for significant proportions of AIS7 ,8 and portend a dismal prognosis.9–14 Intra-arterial (IA) thrombolysis has been shown to be superior to IV thrombolytic therapy for these patients.15–17 One explanation is the lower rates of recanalization associated with IV thrombolysis18 as opposed to either mechanical thrombectomy,11 ,14 local IA thrombolysis19 or a combination of both.20–22 Thus there is an emerging trend incorporating EV therapy for acute stroke patients presenting with an LVO. The goal of the current study was to conduct a direct comparison of the two treatment modalities and offer preliminary data for a potential prospective trial.



The null hypothesis for this study stated that there is no difference in outcomes between IV thrombolytic therapy and EV stroke therapy for LVO in the anterior circulation.

Patient selection

Institutional review board approval was obtained for this study. We analyzed a prospectively maintained database of 425 patients who had received IV thrombolytic therapy (n=260), EV treatment (n=146) or both (n=19) for AIS over an 8 year period. Since the objective of the study was a direct comparison of IV versus EV therapy, only those patients who had received one or the other but not both were included (n=407). The vascular occlusion site was determined on the baseline CT angiogram (CTA) and patients who did not demonstrate an intracranial vascular occlusion on CTA (n=110) were excluded from the analysis. All of these were in the IV treatment group. Patients with a small vessel occlusion (n=22; IV=19, EV=3) involving either a branch of the anterior cerebral artery or a third order branch of the middle cerebral artery—for example, M3—were also excluded. Additionally, patients with posterior circulation strokes (n=37; IV=21, EV=16) were excluded.

There were 13 patients without a clinical follow-up (EV=3, IV=10). Lastly, one 8-year-old male was excluded. This yielded 223 patients who presented with anterior circulation strokes secondary to an LVO and underwent either IV (n=100) or EV (n=123) therapy. This formed the cohort for the analysis.


The IV therapy was initiated after a complete neurological assessment and comprised recombinant tissue plasminogen activator (rt-PA) administered per standardized guidelines1 and within 3 h of symptom onset. The rt-PA used was alteplase (Activase; Genentech Inc, San Francisco, California, USA). For EV therapy, patients had to be outside the time window for IV treatment or have other contraindications to IV thrombolysis. Compared with IV thrombolysis, which followed a fairly established and standardized protocol, there were no set standard criteria for EV therapy, as discussed in the limitations below. The most consistent criteria were the presence of cerebrovascular occlusion on CTA and absence of large area of early ischemic change on the non-contrast CT. Patients with a large cerebral blood volume abnormality on a baseline perfusion CT study were generally not treated, however the benefit of any doubt was always given to the patient, especially young patients and those who presented early on. All EV procedures were performed from a transfemoral approach, either with conscious sedation or general endotracheal anesthesia. The type of EV treatment included IA thrombolysis with r-tPA, mechanical thrombectomy or a combination of both. Mechanical thrombectomy involved the use of Food and Drug Administration (FDA) approved devices.2 ,3 ,23 Patients in both groups were admitted to the intensive care unit following therapy.

Vascular occlusion site

The vascular occlusion site was determined based on the baseline CTA and was into the intracranial internal carotid artery with extension into the terminus (ICA-T), the main stem of the middle cerebral artery (M1) with or without extension into the middle cerebral artery bifurcation and isolated involvement of the proximal middle cerebral artery bifurcation branches (M2) (figure 1).

Figure 1

Occlusion site. An anterior–posterior angiogram projections shows occlusion of the right internal carotid artery terminus (A), the right M1 (B) and a left M2 (C).


The primary endpoint was measured using the modified Rankin Scale (mRS) score at 90 days or the closest follow-up to 90 days. A good functional outcome was defined as an mRS score of ≤2. The European–Australasian Acute Stroke Study (ECASS) classification was used to grade post-treatment hemorrhages as parenchymal hematoma (PH) or hemorrhagic infarction (HI). The analysis was performed on follow-up CT or MR images reviewed by a neuroradiologist blinded to the outcomes or the treatment arm. We classified PH-1 and PH-2 as significant hemorrhages and HI-1 and HI-2 as non-significant hemorrhages. We did not include recanalization as an outcome as conclusive information regarding recanalization was only available for the EV treatment group. Recanalization as a primary endpoint has been extensively used in the stroke device trials and while this may be important to test device efficacy, a true comparison with the proven IV thrombolytic therapy can only be done with a direct comparison of the clinical outcome.

Statistical analysis

The endpoints for the analysis were clinical outcome and mortality. The significance of simple bivariate associations was assessed using Fisher's exact test for categorical variables, the Student's t test for continuous variables or logistic regression as appropriate. Initial analysis was performed to determine the predictors of outcome in the entire sample followed by a baseline analysis to assess for variations among the two treatment samples. Multivariable logistic regression was then performed assessing several factors simultaneously. The regression model was constructed to account for the effect of variables found to have a p value of <0.1 in the univariate analysis for determining predictors of outcome. All data analysis was performed using JMP statistical software, V.9 (SAS Institute Inc, Cary, North Carolina, USA).


Data from 223 patients were analyzed. Mean age was 71.9 (±15.3) years. There were 98 (43.9%) male and 125 (56.1%) female patients. The mean baseline National Institutes of Health Stroke Scale (NIHSS) score was 16.1 (±7.6). There were 45 (20.2%) patients with an ICA-T occlusion, 107 (48%) patients with an M1 occlusion and 71 (31.8%) patients with an M2 occlusion. The mean time from symptom onset to start of the EV procedure (groin puncture) was 5 h and 59 min (±3 h 16 min).

A good outcome was seen in 81 (36.3%) patients and mortality in 81 (36.3%) patients. A significant hemorrhage was seen in 27 (12.1%) patients. The predictors of outcome and mortality are listed in table 1. Patients with a favorable outcome had a lower mean age and baseline NIHSS score. Significantly more patients with a poor outcome had an ICA-T or M1 occlusion while significantly more patients with a favorable outcome had an M2 occlusion. The presence of significant hemorrhage was associated with a poor outcome. A higher NIHSS score, age, ICA-T occlusion and presence of significant hemorrhage were associated with a higher mortality (table 1).

Table 1

Predictors of outcome and mortality for the entire cohort (n=223)

Comparison of the two treatment groups

A comparison of the baseline characteristics among the EV and IV groups is given in table 2. A good outcome was seen in 55 patients (44.7%) who underwent EV therapy compared with 26 patients (26%) who received IV thrombolysis (p=0.003, OR 2.3, 95% CI 1.3 to 4.1). The death rate was not different in the two groups: 39 patients (31.7%) in the EV therapy group and 42 patients (42%) patients with IV thrombolysis (p=0.1, OR 1.6, 95% CI 0.9 to 2.7). Likewise, the hemorrhage rate was similar in the two treatment arms: a significant hemorrhage was seen in 17 patients (13.8%) in the EV treatment arm and in 10 (10%) patients in the IV thrombolysis arm (p=0.38, OR 0.7, 95% CI 0.3 to 1.6). As shown in table 2, mean age in the EV group was lower than that in the IV group while the composition of the occlusion site was different between the two groups. A significantly higher percentage of patients in the EV group had an M1 occlusion while a significantly higher percentage of patients in the IV group had an M2 occlusion (table 2).

Table 2

Comparison of baseline characteristics between the endovascular and intravenous therapy groups

An analysis of outcomes and mortality between the two groups based on site of occlusion is shown in table 3. This demonstrates that for all occlusion sites, patients undergoing EV treatment had significantly higher odds of a favorable outcome than those with IV thrombolysis and the difference was most prominent for ICA-T and M1 occlusions. For M1 occlusions, patients receiving IV thrombolysis had significantly higher odds of mortality than the EV treatment group (table 3). A multivariable logistic regression analysis was then performed for odds of good versus poor functional outcome taking into account the effect of multiple predictors of outcome as well as the different composition of age and occlusion site in the two treatment subgroups (table 4). This shows that EV therapy, younger age and M2 occlusions were the most significant independent predictors of a good outcome while a higher NIHSS score and LVO (ICA-T or M1) were the most significant independent predictors of mortality.

Table 3

Comparison of outcome and mortality between the two treatment groups based on site of occlusion

Table 4

Multivariable logistic regression for clinical outcome odds of favorable versus poor and no mortality versus mortality


Acute large vessel ischemic strokes pose a significant challenge to intravenously administered thrombolytic therapy. An LVO is a significant predictor of outcome in patients undergoing stroke therapy13 ,14 and unless recanalized, these patients do poorly.13 ,14 ,24 IV rt-PA has not been shown to be effective for recanalization of these proximal vessels18 ,25 due to a large thrombus burden10 ,26 and hence has limited efficacy in impacting outcomes.10–14 27–29 In 103 patients with CTA diagnosed LVO who received IV rt-PA and had a post-infusion angiogram, successful recanalization was seen in only 11.7% of patients.30 The rate of recanalization was 4.4% for ICA-T, 32.3% for M1 and 30.8% for M2 occlusions.30 In another study of 37 patients with documented cerebrovascular occlusion on CTA, catheter angiography following IV rt-PA administration (at a median time of 120 min) demonstrated a 12.5% recanalization rate for ICA or M1 and 27.3% for M2.31 Another trial of 139 patients reported very low recanalization rates for both ICA-T and M1 occlusions32 with no difference in day 1 recanalization between patients who received IV rt-PA versus those who did not.32

Prolyse in Acute Cerebral Thromboembolism II (PROACT-II) was one of the first EV randomized trials showing a benefit of IA thrombolysis for AIS secondary to LVO, in that case the middle cerebral artery.6 The recent SYNTHESIS pilot trial randomizing patients presenting within 3 h to IV or IA alteplase showed improved outcomes and mortality with IA therapy compared with IV.28 Based on the pilot data, an expanded randomized trial of IV versus EV therapy has been suggested.29 Our mean time to groin puncture in the EV group of 6 h is similar to the stroke device trials.2 ,3 ,23 Despite this longer time to initiation of the procedure, patients had better outcomes with EV therapy. Thus while time to treatment is important, the presence of an LVO such as the ICA-T or M1 trumps time when it comes to affecting outcomes. One valid question is why PROACT-II remains the only trial showing a positive benefit for IA thrombolysis? The Food and Drug Administration approval of IV rt-PA may have contributed to this, in addition to inadequate statistical power in some trials.33 ,34 A recent meta-analysis of IA thrombolysis showed higher rates of recanalization and good functional outcomes in patients receiving IA fibrinolysis.35

EV therapy is currently reserved for patients who are outside the IV ‘time window’, ineligible for IV rt-PA or refractory to IV thrombolysis. This last criterion is arbitrarily determined, as the literature does not define a ‘time period’ for IV rt-PA resistance. The National Institute of Neurological Disorders and Stroke (NINDS) trial1 demonstrated improvement in outcomes at 3 months but all the stoke device trials3 ,23 ,36 have used inconsistent criteria, typically a lack of neurological improvement in 1 h, to determine a failed response to IV rt-PA. In reality, failure of a response to IV thrombolysis has become a surrogate to identify patients with a LVO that can then undergo EV therapy. The almost ubiquitous use of CTA in acute stroke imaging makes this selection process based on ‘failed IV rt-PA’ obsolete as patients presenting within 3 h of symptom onset can be readily identified as having an LVO and the feasibility of randomizing patients based on CTA has been established.27

A valid argument in favor of administering IV rt-PA without any patient selection other than time is its wider availability. However, with an increasing physician work force and a push from hospitals to deliver advanced stroke therapy, EV stroke interventions have the potential of becoming more accessible. Another argument for IV rt-PA is that it may not increase the risk of hemorrhagic complications in patients subsequently undergoing an EV procedure.36 Even if that is the case, patients with a full dose of IV rt-PA are less likely to receive local IA thrombolysis and more likely to undergo only mechanical thrombectomy. Local IA thrombolysis has been shown to be an independent predictor of favorable outcomes in patients undergoing EV stroke therapy.19 ,22 Furthermore, the pharmacokinetics of alteplase37 ,38 and its mechanism of action support the local delivery at the clot surface as potentially having a higher efficacy in thrombolysis than its systemic administration. None of our patients with an ICA-T occlusion and only 10% with an M1 occlusion benefitted from IV thrombolysis (table 3). These patients are least likely to achieve recanalization from IV rt-PA administration25 ,39 and so constitute the ideal candidate for EV therapy. EV therapy is shown to be safe within the first 3 h40 and an argument for instituting EV therapy for an LVO without a ‘trial’ of IV thrombolysis is rational.

There is a documented increase in recanalization over time—that is, early (<6 h) and late recanalization (at 24 h).41 ,42 Studies have also shown that the earlier the recanalization, the better the outcome.30 ,43 ,44 Some patients in addition may derive benefit from recanalization beyond 6 h due to a persistent penumbra.45 Studies have also shown that improving door to needle times may improve outcomes in EV therapy.46 Current recommendations for stroke centers include a door to CT time of 25 min and a door to needle time of 60 min for IV rt-PA.47–49 However, there are no such mandates for EV therapy. Studies analyzing the time profiles of EV therapy50 demonstrate sufficient room for improvement along the entire stroke therapy chain. If this is achieved, good outcomes from EV stroke therapy are likely to be higher than what are currently realized. A change in approach for LVOs may involve the concurrent administration of IV rt-PA and EV therapy rather than a linear approach of IV rt-PA, lack of symptomatic improvement and then initiation of EV treatment.


This is a single center retrospective analysis spread over an 8 year period. All cases that received IV rt-PA did so under standardized published guidelines. However, other than a documented LVO on CTA and lack of a large hypodensity area on non-contrast CT, no standard inclusion criteria were consistently followed for EV procedures. The EV procedures themselves evolved with time as newer devices and techniques became available. Therefore, while the IV group constituted a fairly homogeneous population, the EV group was heterogeneous. As such, any conclusions from the data have to be viewed taking into account this heterogeneity.


Large vessel strokes are a major source of morbidity, mortality and healthcare cost, and developing a focused treatment strategy for these patients is important. The current analysis of over 200 patients shows that for LVOs, EV therapy is a significant independent predictor of outcome with almost four times the odds of achieving a favorable outcome compared with IV thrombolysis. These higher odds are without any increase in hemorrhagic complications or mortality and despite being administered further out from symptom onset. These conclusions are based on a retrospective analysis without strict controls or standardized protocols. Whether these odds hold up in a controlled randomized trial remains to be seen. The data presented here and in the literature however strongly support the idea that such a trial can be rationally contemplated.



  • Contributors ATR contributed to the study design, methodology and analysis. GRH contributed to the statistical analysis and results. JSC and DR contributed to data collection and discussion. KR and TDR contributed to the discussion section.

  • Competing interests None.

  • Ethics approval The study was approved by the institutional review board.

  • Provenance and peer review Not commissioned; externally peer reviewed.